What MSD Czech Republic does

MSD Czech Republic is the Czech subsidiary of Merck & Co., Inc. (NYSE: MRK), operating in the country since 1992 through three legal entities: Merck Sharp & Dohme s.r.o. (Human Health), MSD Czech Republic s.r.o. (Finance & IT), and INTERVET, s.r.o. (Animal Health). The company markets a diversified pharmaceutical and vaccine portfolio spanning oncology (Keytruda, Temodal), vaccines (Gardasil, Gardasil 9, Vaxneuvance, RotaTeq, Vaxelis), infectious diseases (Zepatier, Lagevrio, Prevymis), diabetes (Januvia, Janumet), pulmonary hypertension (Winrevair, Adempas), anesthesia (Bridion, Esmeron), and animal health products. Revenue is generated through direct distribution to hospitals and pharmacies and through authorized wholesale distributors, with pricing governed by the Czech State Institute for Drug Control (SÚKL) reimbursement framework. The customer base spans healthcare professionals, hospitals, pharmacies, and veterinary practitioners across the Czech Republic and Slovakia.

Beyond its commercial pharma operations, MSD Czech Republic hosts two strategically significant global functions for Merck & Co. The Prague MSD Technology Center, established in 2014, provides enterprise-wide software engineering, data science, digital manufacturing, research and lab IT, and infrastructure services, supported by advanced analytics and AI/ML capabilities including production-grade generative AI, NLP, and the award-winning ALPS manufacturing optimization algorithm. The Global Business Solutions (GBS) hub, established in 2017, delivers finance and accounting shared services — Account to Report, Financial Planning & Analysis, Source to Settle, Order to Cash, and Card Administration — across the global MSD network. The Czech workforce of 1,800+ spans 90+ nationalities and has earned Top Employer certification for five consecutive years (2025, 2026), reflecting the operation's role as a critical talent and capability node within Merck & Co.'s global delivery model.

Name

MSD Czech Republic

Legal name

Merck Sharp & Dohme s.r.o.

Website

https://msd.cz

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

MSD Czech Republic is the Czech subsidiary of Merck & Co., Inc., marketing prescription medicines, vaccines, and animal health products to healthcare professionals, hospitals, and pharmacies, while hosting the Prague MSD Technology Center and Global Business Solutions shared services hub for global Merck operations.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)

Keywords

• Prescription pharmaceuticals
• Human vaccines
• Oncology therapeutics
• Animal health products
• Biopharmaceutical research

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain, Infrastructure

Revenue model

1. Prescription Medicines: MSD generates revenue primarily from the sale of prescription pharmaceutical products across therapeutic areas including oncology, immunology, vaccines, infectious diseases, diabetology, cardiology, and anesthesiology. Products include Keytruda, Gardasil, Januvia, Zepatier, and others. Revenue is realized through direct sales to hospitals and pharmacies as well as wholesale distribution.
2. Vaccines: MSD supplies a broad portfolio of vaccines including those for hepatitis A, rotavirus, pneumococcal infections, HPV (Gardasil, Gardasil 9), measles/mumps/rubella, varicella, and others. Sold to healthcare providers, governments, and through distribution channels.
3. Animal Health Products: MSD Animal Health (Intervet) offers veterinary medicines, vaccines, and services for animal owners and veterinarians in the Czech Republic and Slovakia. Revenue generated through veterinary practices and animal health distributors.
4. Global Business Solutions Services: Internal shared services organization providing finance, accounting, procurement, and operational support to MSD entities globally. As an internal service center, it enables cost-efficiency across the enterprise rather than generating external revenue directly.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

MSD Czech Republic manufactures, supplies, and distributes prescription pharmaceutical medicines and vaccines across therapeutic areas including oncology (Keytruda, Temodal), vaccines (Gardasil 9, Vaxneuvance, Pneumovax 23, RotaTeq, Vaxelis), diabetes (Januvia, Janumet), infectious diseases (Zepatier, Lagevrio, Prevymis), anesthesia (Bridion, Esmeron), and pulmonary hypertension (Winrevair, Adempas). The company also operates an animal health division (Intervet) supplying veterinary medicines and vaccines, and hosts a Technology Center and Global Business Solutions shared services hub providing internal IT, data science, and finance services to MSD entities globally.

Product overview

MSD Czech Republic operates as the Czech subsidiary of Merck Sharp & Dohme, a global biopharmaceutical company with 130+ years of history. The company offers a diversified portfolio of prescription medicines and vaccines across multiple therapeutic areas including oncology (Keytruda, Temodal), vaccines (Gardasil 9, Pneumovax 23, Vaxneuvance, RotaTeq, Vaxelis), diabetes (Januvia, Janumet), infectious diseases (Zepatier, Lagevrio, Prevymis), and anesthesia (Bridion, Esmeron). Beyond pharmaceuticals, the Prague office hosts a Technology Center providing software engineering, data science, and IT services globally, and a Global Business Solutions hub delivering finance and accounting shared services. The company also maintains animal health operations through MSD Animal Health.

Differentiator

Problem solved

Functional benefit

Brands

• MSD Animal Health: Veterinary division of MSD focusing on animal health products, vaccines, and services
• MSD for Mothers
• MSD Technology Center
• Global Business Solutions (GBS)

Products and services

• Keytruda (pembrolizumab) Immuno-oncology prescription medicine (pembrolizumab) used by oncologists for the treatment of multiple cancer types including malignant melanoma, lung cancer, and bladder cancer.
• Gardasil 9 HPV vaccine providing protection against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, 58) for prevention of cervical cancer and other HPV-related tumors.
• Winrevair (sotatercept)

Quantifiable outcome

• Pulmonary arterial hypertension (PAH) affects ~100,000 people in Czech Republic; MSD supports patients through awareness campaigns and treatment access programs.
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Association of Social Responsibility (CSR Associace)coreStrategic or Co-development Partner · 14 March 2025MSD Czech Republic co-hosted the Sustainable Brunch event with the Association of Social Responsibility in celebration of International Women's Day. The event brought together over 120 leaders, innovators, and change-makers to honor women's achievements and discuss barriers to gender equality. MSD collaborated on the Business Attire Collection initiative supporting eight local NGOs.
• Nadace MomentminorStrategic or Co-development Partner · 14 March 2025MSD collaborated with Nadace Moment to organize the Business Attire Collection at the Sustainable Brunch event. The initiative collected unworn professional clothing to raise funds for eight local NGOs, reinforcing MSD's role in community giving back.

Scale indicators9 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Pfizer Czech Republic: Czech subsidiary of a top global biopharma, also operating in oncology, vaccines, inflammation/immunology, and primary care with both direct and wholesale distribution channels — closely comparable to MSD Czech Republic's structure and product breadth.
• Roche Czech Republic: Czech arm of Roche, with a deep oncology/immunology portfolio and similar direct-to-hospital/wholesale distribution model; directly comparable on therapeutic-area mix and HCP engagement approach.
• Novartis Czech Republic: Swiss pharma major's Czech subsidiary with overlapping prescription-medicines portfolio across oncology, cardiology, immunology, and ophthalmology — direct competitor for hospital procurement and SÚKL reimbursement listings.
• Sanofi Czech Republic: Sanofi's Czech operations compete with MSD across vaccines, immunology, diabetes, and rare disease — comparable enterprise field-sales GTM and similar dual-channel distribution via wholesalers and direct pharmacy/hospital sales.
• Johnson & Johnson (Innovative Medicine) Czech Republic: J&J's pharmaceutical arm in Czech Republic competes with MSD in oncology, immunology, and infectious diseases, with an analogous mix of HCP-targeted field sales and hospital-channel distribution.
• GSK Czech Republic: GSK's Czech subsidiary is a direct vaccine competitor (HPV, pediatric, pneumococcal, hepatitis) and competes in HIV, respiratory, and specialty medicines — directly comparable on the vaccine-portfolio side.
• AstraZeneca Czech Republic: AZ's Czech entity competes in oncology, respiratory, cardiovascular, and diabetes via direct and wholesale channels — directly comparable on therapeutic-area overlap with MSD's Januvia, Keytruda, and cardiovascular franchises.
• Eli Lilly Czech Republic: Lilly's Czech subsidiary competes with MSD in diabetes (Januvia/Janumet vs. Trulicity/Mounjaro), oncology, immunology, and neuroscience, with a similarly enterprise-field-sales GTM.
• AbbVie Czech Republic: AbbVie's Czech operations compete with MSD in immunology, oncology, and neuroscience — comparable specialty-care enterprise field-sales motion and direct hospital distribution via SÚKL-managed reimbursement.

Broad incumbents

• Bayer Czech Republic: Bayer's Czech pharmaceutical operations overlap with MSD in cardiology, women's health, and radiology, while Bayer is also a broader life-science incumbent (CropScience, Consumer Health) — broader-than-MSD but materially comparable on the pharma side.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCzw0K-BF3OzlQVYn6BGHQQw
• Facebookfacebook.com/MSDInvents
• LinkedInlinkedin.com/company/msdczech
• Instagraminstagram.com/msdinvents
• Xx.com/MSDczech

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSD Czech Republic